New study tracks Real-World treatment of rare kidney disease in china
NCT ID NCT06099236
First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study observes 367 Chinese patients with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. Researchers will track how patients are treated in routine care and monitor their health for up to 12-24 months. The goal is to better understand the disease and current treatment patterns in China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
367 people
The number who actually took part.
- Started
-
Jan 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
paediatric and adult patients diagnosed with aHUS
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants are eligible to be included in the study. Age 1. Patients of any age, who are diagnosed as aHUS by a professional physician (first epi-sode or relapse). Type of Patient and Disease Characteristics 2. Evidence of TMA, including thrombocytopenia, evidence of hemolysis, and kidney dys-function, based on the following laboratory findings, should be recorded within 2 weeks time frame: 1. Platelet count \< 150,000 per microliter (μL), and 2. Mechanic hemolytic anemia evident by LDH ≥ 1.5 × upper limit of normal (ULN), and hemoglobin ≤ lower limit of normal (LLN) for age and gender and 3. Serum creatinine level ≥ ULN in adults (≥18 years of age), or ≥ 97.5th percentile for age at screening in children (patients who require dialysis for acute kidney injury are also eligi-ble). 3. Gender: Male and/or female. Informed Consent 4. Willing and able to give written informed consent and comply with the study visit schedule as described in Section 6.2.1. For patients \< 18 years of age, patient's legal guardian must be willing and able to give written informed consent and the patient must be willing to give written informed assent (if applicable as determined by the central. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: Medical Conditions 1. Patients who were diagnosed with HUS only due to Shiga toxin-producing Escherichia coli (STEC). 2. Patients who were diagnosed with TTP (ADAMTS13 activity \<10%). Other Exclusions 3. Unable to give written informed consent. 4. Any medical or psychological condition that, in the opinion of the Investigator, could increase the risk to the participant by participating in the study or confound the outcome of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atypical hemolytic uremic syndrome(AHUS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Beijing, Beijing Municipality, China
-
Research Site
Chongqing, Sichuan, China
-
Research Site
Anhui, China
-
Research Site
Beijing, China
-
Research Site
Chongqing, China
-
Research Site
Fujian, China
-
Research Site
Guangdong, China
-
Research Site
Guangxi, China
-
Research Site
Guizhou, China
-
Research Site
Hainan, China
-
Research Site
Hebei, China
-
Research Site
Henan, China
-
Research Site
Hong Kong, China
-
Research Site
Hubei, China
-
Research Site
Hunan, China
-
Research Site
Jiangsu, China
-
Research Site
Jiangxi, China
-
Research Site
Liaoning, China
-
Research Site
Shaanxi, China
-
Research Site
Shandong, China
-
Research Site
Shanghai, China
-
Research Site
Shanxi, China
-
Research Site
Sichuan, China
-
Research Site
Tianjin, China
-
Research Site
Xinjiang, China
-
Research Site
Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.